Unité de Fabrication des Médicaments S.A.
Price History & Performance
|Historical stock prices|
|Current Share Price||د.ت7.27|
|52 Week High||د.ت6.69|
|52 Week Low||د.ت10.95|
|1 Month Change||6.91%|
|3 Month Change||2.39%|
|1 Year Change||-31.29%|
|3 Year Change||-13.45%|
|5 Year Change||-22.25%|
|Change since IPO||-30.17%|
Recent News & Updates
|UMED||TN Pharmaceuticals||TN Market|
Return vs Industry: UMED underperformed the TN Pharmaceuticals industry which returned 89.9% over the past year.
Return vs Market: UMED underperformed the TN Market which returned -1.1% over the past year.
Stable Share Price: UMED is not significantly more volatile than the rest of TN stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: UMED's weekly volatility (3%) has been stable over the past year.
About the Company
Unité de Fabrication des Médicaments S.A. develops, manufactures, markets, and sells generic medicines under the UNIMED brand in Tunisia, Africa, Asia, and Europe. The company’s products include ophta-ORL solutions, liquids for injections, penicillin powders, cephalosporins for injections, inhalations, and perfusion solutions, as well as vaigtaine products in approximately 40 presentations for various therapeutic classes. It also manufactures medicines for third party laboratories.
Unité de Fabrication des Médicaments Fundamentals Summary
|UMED fundamental statistics|
Is UMED overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|UMED income statement (TTM)|
|Cost of Revenue||د.ت40.90m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.20|
|Net Profit Margin||7.28%|
How did UMED perform over the long term?See historical performance and comparison
Is Unité de Fabrication des Médicaments undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: UMED (TND7.3) is trading below our estimate of fair value (TND10.71)
Significantly Below Fair Value: UMED is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: UMED is poor value based on its PE Ratio (37.3x) compared to the African Pharmaceuticals industry average (9.5x).
PE vs Market: UMED is poor value based on its PE Ratio (37.3x) compared to the TN market (11.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate UMED's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: UMED is overvalued based on its PB Ratio (2.2x) compared to the XF Pharmaceuticals industry average (1.5x).
How is Unité de Fabrication des Médicaments forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Unité de Fabrication des Médicaments has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Unité de Fabrication des Médicaments performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: UMED has high quality earnings.
Growing Profit Margin: UMED's current net profit margins (7.3%) are lower than last year (13%).
Past Earnings Growth Analysis
Earnings Trend: UMED's earnings have declined by 2.7% per year over the past 5 years.
Accelerating Growth: UMED's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: UMED had negative earnings growth (-49.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10%).
Return on Equity
High ROE: UMED's Return on Equity (6%) is considered low.
How is Unité de Fabrication des Médicaments's financial position?
Financial Position Analysis
Short Term Liabilities: UMED's short term assets (TND73.4M) exceed its short term liabilities (TND19.9M).
Long Term Liabilities: UMED's short term assets (TND73.4M) exceed its long term liabilities (TND26.1M).
Debt to Equity History and Analysis
Debt Level: UMED's debt to equity ratio (32.8%) is considered satisfactory.
Reducing Debt: UMED's debt to equity ratio has increased from 5.2% to 32.8% over the past 5 years.
Debt Coverage: UMED's debt is well covered by operating cash flow (63.9%).
Interest Coverage: UMED's interest payments on its debt are well covered by EBIT (4.2x coverage).
What is Unité de Fabrication des Médicaments's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate UMED's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate UMED's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if UMED's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if UMED's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: UMED is not paying a notable dividend for the TN market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of UMED's dividend in 3 years as they are not forecast to pay a notable one for the TN market.
How experienced are the management team and are they aligned to shareholders interests?
Mr. Ridha Charfeddine is the Chief Executive Officer at Unité de Fabrication des Médicaments since June 12, 2020. He is the President of the Board of Directors at Société UNIMED.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Unité de Fabrication des Médicaments's employee growth, exchange listings and data sources
- Name: Unité de Fabrication des Médicaments
- Ticker: UMED
- Exchange: BVMT
- Founded: 1989
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: د.ت237.760m
- Shares outstanding: 32.00m
- Website: https://www.unimed.com.tn
Number of Employees
- Unité de Fabrication des Médicaments
- Industrial Zone Kalaa Kebira, BP 38
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 16:24|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.